A Phase 1/2 interventional study of TNM001 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd.. Completed at 6 sites in China. Open to participants aged Up to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-28.
Sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 1/2, and was the 5th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 18+ · Healthy volunteers
Simcere Pharmaceutical Co., Ltd · Sites in China
Ages 1 mo–36 mo
Shanghai Ark Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–85
Kexing Biopharm Co., Ltd. · Sites in China
Ages 2 mo–2 yrs
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: Up to 1 Year · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 10
First in 2019; this study’s year is marked. 3 started in 2022.
This study's enrollment of 31 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 132 across the 25 interventional studies, 816 across the 5 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 30 have an industry lead sponsor. The 10 most frequent:
Zhuhai Trinomab Pharmaceutical Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Zhuhai Trinomab Pharmaceutical Co., Ltd. has 3 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Syncytial Virus Infections with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402512Phase 3Simcere Pharmaceutical Co., LtdA Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children | 2027-03-31 |
| NCT06363370Phase 3Kexing Biopharm Co., Ltd.Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | 2027-06-30 |
| NCT06645665Shenzhen Shenxin Biotechnology Co., LtdA Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above | 2027-04 |
| NCT07582796Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. | 2027-09-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profile of TNM001 injection in healthy preterm and term infants. The main questions it aims to answer are:
This phase Ib/IIa study is designed to assess the safety, tolerability, and pharmacokinetics (PK) profile TNM001 in healthy preterm and term infants. This study will also compare the incidence of Respiratory Syncytial Virus(RSV) infection between different doses of TNM001 and placebo, which will be used to select the dose to be studied in the later phase of clinical trials of TNM001. Approximately 30 subjects will be randomized and will be dosed once on Day 1 and followed up until Day 151. Around 6 investigational study centres participate in the study.
Key Inclusion Criteria:
Key Exclusion Criteria:
low dose administered
Biological: TNM001
medium dose administered
Biological: TNM001
high dose administered
Biological: TNM001
placebo administered
Biological: Placebo
intramuscular injection
intramuscular injection
Safety and tolerability of TNM001 Injection
Type and incidence of adverse events and serious adverse events
Time frame: 150 days post dose
Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of TNM001
The pharmacokinetic (PK) parameter AUC (0-infinity) will be estimated based on the serum concentrations of TNM001
Time frame: 150 days post dose
Maximum Observed Serum Concentration (Cmax) of TNM001
The Cmax is the maximum observed serum concentration of TNM001
Time frame: 150 days post dose
Terminal Elimination Half Life (t1/2) of TNM001
Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum
Time frame: 150 days post dose
Serum anti-RSV neutralizing antibodies titer levels in each dose cohort
To summarize the proportion of subjects with severalfold increase after dosing compared to the predose (baseline)
Time frame: 150 days post dose
Anti-drug antibody (ADA) positive rate of TNM001
The evaluation indicator of immunogenicity is the ADA positive rate in subjects
Time frame: 150 days post dose
Lower respiratory tract infection(LRTI)
The incidence of LRTI
Time frame: 150 days post dose
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Jun 2023, 8 months.
Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Retavibart
Respiratory Syncytial Virus Infections →
Zhuhai Trinomab Pharmaceutical Co., Ltd.